TLR Agonists Modulate PD-1 Expression on T Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer vaccines, particularly those for prostate cancer, face challenges in eliciting a strong anti-tumor immune response due to low immunogenicity and limited effectiveness, with existing methods failing to adequately stimulate CD8+ T cell responses and overcome immune checkpoint blockade limitations.
Innovation Solution
Administering TLR1/2 or TLR7 agonists in combination with immunotherapeutic agents, such as vaccines, to enhance immune responses by down-regulating PD-1 expression on activated immune cells, thereby increasing the efficacy of anti-tumor responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current anti-cancer DNA vaccines are used, then they are safe and immunologically effective, but they produce weak anti-tumor responses and require multiple administrations
Solution Approach 1:
The patent modifies the immune response parameters by combining DNA vaccines with TLR agonists (such as CpG oligonucleotides for TLR9 or poly(I:C) for TLR3), which changes the activation state of dendritic cells and T cells. This parameter change in the immune activation pathway leads to stronger anti-tumor responses and potentially reduced need for multiple administrations.
Solution Approach 2:
The invention uses composite immunotherapeutic formulations combining DNA vaccine plasmids with TLR agonist molecules. This composite approach integrates multiple functional elements (antigen expression from DNA + TLR activation) to achieve synergistic effects that strengthen the anti-tumor response and improve vaccine efficacy.
2Reliability
If immune checkpoint blockades are used, then they show promise in treating many cancers, but prostate cancer has been notoriously unaffected
Solution Approach 1:
The patent applies local quality modification by targeting specific TLR pathways (TLR3, TLR7, TLR9) that can be activated by specific agonists. This localized activation of innate immune pathways creates a more potent and adaptable response that may overcome the resistance to checkpoint blockades observed in prostate cancer, while maintaining effectiveness across different cancer types.
Solution Approach 2:
The TLR agonists act as intermediary molecules that bridge the gap between the DNA vaccine and the adaptive immune response. By first activating TLRs on dendritic cells, these intermediaries enhance the overall immune activation and may restore sensitivity to immunotherapeutic agents in cancers that are resistant to standard checkpoint blockades.
3Productivity
If methods to increase the number of T cells stimulated/activated upon vaccination are used, then immunogenicity may improve, but activation-induced PD-1 expression increases which limits effectiveness
Solution Approach 1:
The patent converts the harmful effect of T cell activation (which normally induces PD-1 expression and limits effectiveness) into a benefit by simultaneously activating TLRs. The TLR activation creates a dual signal that promotes T cell proliferation while modulating PD-1 expression, transforming the activation-induced limitation into an enhanced immune response opportunity.
Solution Approach 2:
The invention changes the parameter of T cell activation by introducing TLR signaling parallel to antigen stimulation. This dual parameter activation (antigen + TLR ligand) modifies the activation-induced PD-1 expression pattern, creating a more favorable balance between T cell proliferation and functional effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances anti-tumor immune responses, leading to reduced tumor growth and, in some cases, complete tumor regression, by promoting a PD-1low phenotype in activated T cells, which are less susceptible to immune checkpoint-mediated regulation.
Implementation Method 1
TLR1/2 or TLR7 agonists in combination with immunotherapeutic agents, such as vaccines, to enhance immune responses by down-regulating PD-1 expression on activated immune cells
Implementation Method 2
promoting a PD-1low phenotype in activated T cells, which are less susceptible to immune checkpoint-mediated regulation
Data Source
AI summary
The present invention is directed toward methods of increasing the immune response to an antigen using TLR1/2 agonist and/or TLR7 agonist in combination with a T cell activating treatment, for example, a vaccine. In some aspects, the present invention provides methods of enhancing an anti-tumor response comprising administering at least one TLR1/2 agonist and/or at least one TLR7 agonist in combination with an immunotherapeutic agent.